Non-invasive neuroimaging modalities, and in particular magnetic resonance imaging (MRI), have become indispensable tools for diagnosis, prognosis and treatment monitoring in clinical practice, as well as for understanding brain function in neuroscience research. Magnetic resonance spectroscopy (MRS) is one MRI modality that provides in vivo access to cellular composition (by measuring neurochemical concentrations) and to cellular function (by measuring metabolic activity). The goal of my laboratory is to bring the versatility of high field, in vivo MRS to bear on longstanding biomedical questions and to increase the utility of this powerful technology in clinical practice.
A major focus has been to establish in vivo 1H MRS biomarkers of neurodegeneration, in parallel studies with patients and transgenic mouse models, with particular emphasis on spinocerebellar ataxias and Parkinson’s disease. Such biomarkers are expected to facilitate early disease detection and treatment monitoring in pre-clinical and clinical trials. These are collaborative studies with colleagues from Departments of Neurology, Lab Medicine and Pathology, Neuroscience, Experimental and Clinical Pharmacology and Biostatistics.
A second goal has been to determine the effects of diabetes and the hypoglycemic consequences of intensive insulin therapy on brain glucose and glycogen metabolism in humans. In particular, we utilize 1H and 13C MRS to elucidate pathogenic mechanisms of hypoglycemia unawareness syndrome, the limiting factor in achieving normoglycemia in patients with type 1 and advanced type 2 diabetes. For these studies we collaborate with Dr. Elizabeth Seaquist from the Department of Medicine.
(For a comprehensive list of recent publications, refer to PubMed, a service provided by the National Library of Medicine.)
- Zeydan B, Deelchand DK, Tosakulwong N, Lesnick TG, Kantarci OH, Machulda MM, Knopman DS, Lowe VJ, Jack CR Jr, Petersen RC, Öz G, Kantarci K. Decreased glutamate levels in patients with amnestic mild cognitive impairment: An sLASER proton MR dpectroscopy and PiB-PET study. J Neuroimaging. 2017;27(6):630-636.
- Coles LD, Tuite PJ, Öz G, Mishra UR, Kartha RV, Sullivan KM, Cloyd JC, Terpstra M. Repeated-dose oral N-acetylcysteine in Parkinson's disease: Pharmacokinetics and effect on brain glutathione and oxidative stress. J Clin Pharmacol. 2017 Sep 22. doi: 10.1002/jcph.1008.
- Seaquist ER, Moheet A, Kumar A, Deelchand DK, Terpstra M, Kubisiak K, Eberly LE, Henry PG, Joers JM, Öz G. Hypothalamic glucose transport in humans during experimentally induced hypoglycemia-associated autonomic failure. J Clin Endocrinol Metab. 2017;102:3571-3580.
- Öz G, DiNuzzo M, Kumar A, Moheet A, Khowaja A, Kubisiak K, Eberly LE, Seaquist ER. Cerebral glycogen in humans following acute and recurrent hypoglycemia: Implications on a role in hypoglycemia unawareness. J Cereb Blood Flow Metab. 2017 Aug;37(8):2883-2893.
- Deelchand DK, Kantarci K, Öz G. Improved localization, spectral quality, and repeatability with advanced MRS methodology in the clinical setting. Magn Reson Med. 2017 Jun 15. doi: 10.1002/mrm.26788.
- Cheong I, Marjańska M, Deelchand DK, Eberly LE, Walk D, Öz G. Ultra-high field proton MR spectroscopy in early-stage amyotrophic lateral sclerosis. Neurochem Res. 2017;42:1833-1844.
- Maliszewski-Hall AM, Alexander M, Tkáč I, Öz G, Rao R. Differential effects of intrauterine growth restriction on the regional neurochemical profile of the developing rat brain. Neurochem Res. 2017;42(1):133-140.
- Joers JM, Deelchand DK, Kumar A, Moheet A, Seaquist E, Henry PG, Öz G. Measurement of hypothalamic glucose under euglycemia and hyperglycemia by MRI at 3T. J Magn Reson Imaging. 2017;45(3):681-691.
- Terpstra M, Cheong I, Lyu T, Deelchand DK, Emir UE, Bednařík P, Eberly LE, Öz G. Test-retest reproducibility of neurochemical profiles with short-echo, single-voxel MR spectroscopy at 3T and 7T, Magn Reson Med. Magn Reson Med. 2016;76(4):1083-91.
- Brouillette AM, Öz G, Gomez CM. Cerebrospinal fluid biomarkers in spinocerebellar ataxia: A pilot study. Dis Markers. 2015;2015:413098.
- Öz G, DiNuzzo M, Kumar A, Moheet A, Seaquist ER. Revisiting glycogen content in the human brain. Neurochem Res. 2015;40(12):2473-81.
- Öz G. MR Spectroscopy: A longitudinal biomarker for substantia nigra pathology in Parkinson's Disease? Mov Disord. 2015;30(10):1304-5.
- Bednařík P, Moheet A, Deelchand DK, Emir UE, Eberly LE, Bareš M, Seaquist ER, Öz G. Feasibility and reproducibility of neurochemical profile quantification in the human hippocampus at 3 T. NMR Biomed. 2015;28(6):685-93.
- Deelchand DK, Adanyeguh IM, Emir UE, Nguyen TM, Valabregue R, Henry PG, Mochel F, Öz G. Two-site reproducibility of cerebellar and brainstem neurochemical profiles with short-echo, single-voxel MRS at 3T. Magn Reson Med. 2015;73(5):1718-25.
- Öz G, Kittelson E, Demirgöz D, Rainwater O, Eberly LE, Orr HT, Clark HB. Assessing recovery from neurodegeneration in spinocerebellar ataxia 1: Comparison of in vivo magnetic resonance spectroscopy with motor testing, gene expression and histology. Neurobiol Dis. 2015;74:158-66.
- Khowaja A, Choi IY, Seaquist ER, Öz G. In vivo Magnetic Resonance Spectroscopy of cerebral glycogen metabolism in animals and humans. Metab Brain Dis. 2015;30(1):255-61.
- Adanyeguh IM, Henry PG, Nguyen TM, Rinaldi D, Jauffret C, Valabregue R, Emir UE, Deelchand DK, Brice A, Eberly LE, Öz G, Durr A, Mochel F. In vivo neurometabolic profiling in patients with spinocerebellar ataxia types 1, 2, 3, and 7. Mov Disord. 2015;15;30(5):662-70.
- Armbrust KR, Wang X, Hathorn TJ, Cramer SW, Chen G, Zu T, Kangas T, Zink AN, Öz G, Ebner TJ, Ranum LP. Mutant β-III spectrin causes mGluR1α mislocalization and functional deficits in a mouse model of spinocerebellar ataxia type 5. J Neurosci. 2014;34(30):9891-904.
- Öz G, Alger JR, Barker PB, Bartha R, Bizzi A, Boesch C, Bolan PJ, Brindle KM, Cudalbu C, Dinçer A, Dydak U, Emir UE, Frahm J, González RG, Gruber S, Gruetter R, Gupta RK, Heerschap A, Henning A, Hetherington HP, Howe FA, Hüppi PS, Hurd RE, Kantarci K, Klomp DW, Kreis R, Kruiskamp MJ, Leach MO, Lin AP, Luijten PR, Marjańska M, Maudsley AA, Meyerhoff DJ, Mountford CE, Nelson SJ, Pamir MN, Pan JW, Peet AC, Poptani H, Posse S, Pouwels PJ, Ratai EM, Ross BD, Scheenen TW, Schuster C, Smith IC, Soher BJ, Tkáč I, Vigneron DB, Kauppinen RA; MRS Consensus Group. Clinical proton MR spectroscopy in central nervous system disorders. Radiology. 2014;270(3):658-79.
- Terpstra M, Moheet A, Kumar A, Eberly LE, Seaquist E, Öz G. Changes in human brain glutamate concentration during hypoglycemia: insights into cerebral adaptations in hypoglycemia-associated autonomic failure in type 1 diabetes. J Cereb Blood Flow Metab. 2014;34(5):876-82.
- Emir UE, Tuite PJ, Öz G Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla ¹H MRS. PLoS One, 2012;7(1):e30918.
- Öz G, Tesfaye N, Kumar A, Deelchand DK, Eberly LE, Seaquist ER. Brain glycogen content and metabolism in subjects with type 1 diabetes and hypoglycemia unawareness. J Cereb Blood Flow Metab. 2012;32(2):256-63.
- Emir UE, Auerbach EJ, Van De Moortele PF, Marjańska M, Ugurbil K, Terpstra M, Tkáč I, Öz G. Regional neurochemical profiles in the human brain measured by 1H MRS at 7 tesla using local B1 shimming, NMR Biomed. 2012;25(1):152-60.
- Öz G, Vollmers ML, Nelson CD, Shanley R, Eberly LE, Orr HT, Clark HB. In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 mice. Exp Neurol. 2011 Dec;232(2):290-8.
- Öz G, Iltis I, Hutter D, Thomas W, Bushara KO, Gomez CM. Distinct neurochemical profiles of spinocerebellar ataxias 1, 2, 6, and cerebellar multiple system atrophy. Cerebellum 2011;10(2):208-17.
- Shestov AA, Emir UE, Kumar A, Henry PG, Seaquist ER, Öz G. Simultaneous measurement of glucose transport and utilization in the human brain, Am J Physiology Endocrinol Metab. 2011;301(5):E1040-9.
Current Graduate Students:
Ian Cheong (Neuroscience, University of Minnesota)